Author: Mark Du Bois

Ziccum’s unique LaminarPace technology unleashes the full potential of mRNA and opens the door to entirely new mRNA treatments. This formulation and ambient drying technology transforms delicate liquid biologics into robust, thermostable, high-yield dry powders while preserving mRNA activity.

Join Ziccum at Nordic Life Science Days, meet with the Scientific Director Fabrice Rose to discover LaminarPace, review Ziccum’s solid and extensively validated data for mRNA/LNP and learn how key stability issues can be solved and new therapeutic possibilities created.

Book a meeting here: https://ziccum.com/about-us/contact/

Join Ziccum at RNA Leaders USA Congress on September 4 – 5, 2024, in San Diego, USA and attend our presentation on September 4, 2024, at 16.00 covering the topic: “Enabling the Full Potential of mRNA – with Robust, Particle Engineered, Thermostable Dry Product Forms.”

The presentation will be part of the mRNA Therapeutics & Vaccines: Innovating mRNA Modalities track and will highlight how the disruptive technology LaminarPace formulates and dries the most fragile mRNA/LNP compositions and turns them into robust, thermostable dry powder forms. It will also demonstrate the preserved or even increased mRNA activity of LaminarPace dried materials and how this technology substantially lowers costs, enables new treatments, and allows for particle engineering perfectly suitable for inhalable mRNA – which is unique.

Meet Ziccum CEO Ann Gidner and Scientific Director Fabrice Rose at the event. Book a meeting to learn more about LaminarPace and discover the company’s excellent new mRNA/LNP results here: Contact us – Ziccum

Following a highly valuable tenure, Ziccum’s co-founder and former Chairman Fredrik Sjövall is handing over to Jonas Ekblom, who has been elected Chairman of the Board at Ziccum’s AGM on May 29th, during which Ziccum also added a new member, Valentina Screpanti Sundquist.

Jonas Ekblom

Jonas has over 25 years’ experience in life science and is Associate Professor of Pharmacology at Uppsala University. He has held senior and executive management roles in biotechnology companies in Sweden, the USA and Switzerland, in companies such as Pharmacia, Biovitrum, Promore Pharma, Sequenom, Invitrogen, Pergamum AB and BOWS Pharmaceuticals SA. He is currently Chairman of the board of CombiGene AB (publ) and Oblique Therapeutics AB (publ) and board member of Emplipharm AB (publ) and Moberg Pharma AB (publ).

Valentina Screpanti Sundquist

With almost 20 years’ experience in life science, Valentina Screpanti Sundquist currently is at vaccine company Valneva. She also represents Sweden on behalf of the Swedish Medical Products Agency in the expert group 15, human vaccines and sera, at the European Pharmacopoeia, European Directorate for the Quality of Medicines HealthCare (EDQM, Council of Europe). Valentina has held roles in Swedish biotechnology companies such as BioArctic Neuroscience, Astra Zeneca and Crucell (Johnson and Johnson).

Ziccum CEO Ann Gidner: “we are delighted to welcome two new members to the Ziccum Board, including a Chairman with such an excellent profile and network in industry. Their appointments underline the continued advancement and development of Ziccum. Meanwhile, I want to extend our warmest gratitude to Fredrik Sjövall, who was instrumental in creating Ziccum and taking it forward to the position where it is today. The recent, significant company development has been possible only thanks to his highly engaged support”.

Ziccum CEO Ann Gidner delivered a well-received presentation at BioStock Global Partnering Forum in Lund, Sweden on May 30th, sparking new interest and dialogues with biotech leaders and investors.

Ziccum’s LaminarPace was presented, a formulation and drying technology for delicate liquid biologics: solving stability issues, enabling entirely new delivery options and opening up for new therapeutic indications.  The event was also attended by new Ziccum Finance Manager Christo Vassilev.

CEO: “We won immediate interest and already have several follow-up meetings booked. We’d like to thank everyone who made the event a success!”

Ziccum CEO Ann Gidner and Chairman Fredrik Sjövall are joining Europe’s leading biotech and biopharma companies in Barcelona at the BIO-Europe Spring Partnering conference, 18-20 March.

Ziccum is following up on interesting pipeline dialogues at the event and attended a few valuable and relevant presentations as well.

CEO Ann Gidner: “this whole event is about technology and asset licensing. The partnering set-up provides an intense schedule of one-to-one company meetings. It is very valuable for us to attend regularly, and we enjoy the opportunities to add new dialogues as well”.

On 5^th March 2024, Ziccum management representatives joined over 100 Biotech companies represented at the 5th Biologics World Nordics Forum in central Copenhagen.

The well-attended event brought together biopharmaceuticals developers, CDMOs and technology providers from across the fast-emerging Nordics Biologics market. At the event Ziccum met with several existing contacts and spread further knowledge about the company’s unique drying and formulation technology LaminarPace^TM that transforms delicate biotherapeutics into stable dry powders requiring no cryogenic freezing and well-suited to novel administration routes.

Read this post on LinkedIn

Solving stability and enabling new drug delivery options for next-generation Biologics is key to unlocking a vast potential. How could it work for your Biologic or mRNA project?  Meet Ziccum CEO Ann Gidner and Chairman Fredrik Sjövall at BIO-Europe Spring, Barcelona Spain 16 – 18 March.

Ziccum will be represented at this premier industry event to share the company’s unique technology for cost efficiently formulating and drying liquid biologics as robust thermostable dry powders that require no cryogenic storage and are ideally suited for novel administration routes.

Book a meeting and discover the company’s excellent new mRNA/LNP results, generated in both internal and partnered projects.

Book a meeting here.

Read about Ziccum’s mRNA data and readouts here.